Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.
Saved in:
| Title: | Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system. |
|---|---|
| Authors: | Balshi A; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Dempsey JP; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Manning N; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Leuenberger G; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Baber U; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Sloane JA; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2025 Nov; Vol. 31 (13), pp. 1591-1594. Date of Electronic Publication: 2025 Jun 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1477-0970 |
|---|---|
| DOI: | 10.1177/13524585251342725 |
